Media headlines about Endocyte (NASDAQ:ECYT) have trended somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endocyte earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 43.7823205358499 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently issued reports on ECYT. Cowen and Company reiterated a “hold” rating on shares of Endocyte in a report on Monday, October 2nd. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $2.00 to $7.00 in a report on Tuesday, October 3rd. ValuEngine upgraded shares of Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research cut shares of Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Endocyte currently has a consensus rating of “Hold” and a consensus target price of $7.00.
Endocyte (ECYT) traded up 2.26% during trading on Friday, reaching $4.52. 554,376 shares of the company were exchanged. The firm has a 50-day moving average of $3.16 and a 200-day moving average of $2.16. Endocyte has a 52-week low of $1.17 and a 52-week high of $6.55. The firm’s market cap is $192.44 million.
Endocyte (NASDAQ:ECYT) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.03). The company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. During the same period last year, the business posted ($0.25) earnings per share. On average, equities analysts forecast that Endocyte will post ($1.06) EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/endocyte-ecyt-getting-somewhat-positive-media-coverage-analysis-finds.html.
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.